We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Baseline use of rituximab compared with conventional ...
Use of a tumor necrosis factor inhibitor (TNFi) or triple therapy with conventional, synthetic disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis have similar beneficial effects ...
Rheumatoid arthritis is a chronic autoimmune disorder causing inflammation of synovial joints, leading to pain, stiffness, ...
Please provide your email address to receive an email when new articles are posted on . Half-dose conventional synthetic DMARDs are inferior to stable-dose regimens for preventing flares during a ...
A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...
COVID-19 led many patients to change their use of disease-modifying antirheumatic drugs in the pandemic’s initial months, with or without physician guidance. The COVID-19 pandemic led nearly one-third ...
About one-third of patients prefer in-hospital administration, particularly if they are older or already make frequent visits to the hospital. Most patients with rheumatoid arthritis (RA) would prefer ...
The treat-to-target approach represented a stepped-up model for chronic disease management that only became possible when the available therapies showed the potential for disease remission. The ...
Since their first publication in 2010, the EULAR recommendations for the use of disease-modifying anti-rheumatic treatments (DMARDs) in people with RA have become a most important publication in the ...
Tocilizumab, a biologic disease-modifying antirheumatic drug targeting interleukin 6, reduces disease activity more ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In this study of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback